{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:02:18Z","timestamp":1790136138079,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019688","name":"Department of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It remains unclear if cefazolin inoculum effect (CzIE) translates to poorer clinical outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) infections who were treated with cefazolin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study across 5 hospitals in Ontario, Canada, from 2021 to 2025 included adult patients who received cefazolin treatment for serious MSSA infection based on blood or deep sterile site culture growth. CzIE was defined as a \u22654-fold increase in cefazolin minimum inhibitory concentration to \u226516 \u03bcg\/mL at a high inoculum based on broth microdilution assay. Patients were followed to 90 days. Primary outcome was all-cause mortality. Secondary outcome was microbiological treatment failure based on culture growth of MSSA after 1 week of cefazolin treatment. Potential confounders were adjusted using propensity score weighting, and a competing risk model for microbiological treatment failure was used to account for mortality as a competing event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 259 patients, 92 (35.5%) patients had an MSSA isolate that displayed CzIE. The 90-day mortality rate was 19\/92 (20.7%) and 37\/167 (22.2%) in the CzIE-positive and -negative groups, respectively, with adjusted risk difference of 0.6% (95% CI, \u22129.0% to 10.2%; P = .9060). Microbiological treatment failure occurred in 19\/92 (20.7%) and 10\/167 (6.0%) from the CzIE-positive and -negative groups, respectively, with adjusted subdistribution hazard ratio of 3.12 (95% CI, 1.38\u20137.08; P = .0065) in a competing risk model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CzIE was associated with a significantly increased risk of microbiological treatment failure. CzIE testing may be useful in guiding antibiotic treatment for serious MSSA infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag199","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:41:43Z","timestamp":1775043703000},"page":"e1433-e1442","source":"Crossref","is-referenced-by-count":3,"title":["Cefazolin Inoculum Effect and Cefazolin Microbiological Treatment Failure in Serious Methicillin-Susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    Infections: A Multicenter Retrospective Cohort Study"],"prefix":"10.1093","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0809-5038","authenticated-orcid":false,"given":"Mitchell A","family":"Jeffs","sequence":"first","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5155-5778","authenticated-orcid":false,"given":"Nicole","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwalade","family":"Ogunkoya","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Brody","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University , Hamilton, Ontario ,","place":["Canada"]},{"name":"Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences , Hamilton, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1620-2868","authenticated-orcid":false,"given":"Carson K L","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-3534","authenticated-orcid":false,"given":"Clayton W","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-9374","authenticated-orcid":false,"given":"Ameera","family":"Nemer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaf","family":"Alzarnougi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3664-736X","authenticated-orcid":false,"given":"Calvin Ka-Fung","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma B","family":"Monti","sequence":"additional","affiliation":[{"name":"School of Medicine, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8134-1242","authenticated-orcid":false,"given":"Thuwiba","family":"Al Baluki","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8094-0790","authenticated-orcid":false,"given":"Zong Heng","family":"Shi","sequence":"additional","affiliation":[{"name":"North York General Hospital Department of Pharmacy, , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1510-6310","authenticated-orcid":false,"given":"Xena X","family":"Li","sequence":"additional","affiliation":[{"name":"Shared Hospital Laboratory , Toronto, Ontario ,","place":["Canada"]},{"name":"Sunnybrook Health Sciences Centre Department of Microbiology, , Toronto, Ontario ,","place":["Canada"]},{"name":"North York General Hospital Division of Infectious Diseases, Department of Medicine, , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prameet M","family":"Sheth","sequence":"additional","affiliation":[{"name":"Queen's University Department of Pathology and Molecular Medicine, , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1094-0349","authenticated-orcid":false,"given":"Christopher T","family":"Lohans","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-9934","authenticated-orcid":false,"given":"Anthony D","family":"Bai","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Queen\u2019s University , Kingston, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2026061615215729700_jiag199-B1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026061615215729700_jiag199-B2","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026061615215729700_jiag199-B3","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0140-6736(25)01624-1","article-title":"Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial","volume":"406","author":"Burdet","year":"2025","journal-title":"Lancet"},{"key":"2026061615215729700_jiag199-B4","doi-asserted-by":"crossref","first-page":"e0249521","DOI":"10.1128\/jcm.02495-21","article-title":"Prevalence and characterization of the cefazolin inoculum effect in North American methicillin-susceptible Staphylococcus aureus isolates","volume":"60","author":"Dingle","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2026061615215729700_jiag199-B5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/mdr.2013.0229","article-title":"Clinical implications of cefazolin inoculum effect and \u03b2-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia","volume":"20","author":"Lee","year":"2014","journal-title":"Microb Drug Resist"},{"key":"2026061615215729700_jiag199-B6","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","article-title":"Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure","volume":"53","author":"Nannini","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061615215729700_jiag199-B7","doi-asserted-by":"crossref","first-page":"dlae069","DOI":"10.1093\/jacamr\/dlae069","article-title":"Clinical significance of cefazolin inoculum effect in serious MSSA infections: a systematic review","volume":"6","author":"Lo","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026061615215729700_jiag199-B8","doi-asserted-by":"crossref","first-page":"106429","DOI":"10.1016\/j.ijantimicag.2021.106429","article-title":"Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study","volume":"58","author":"Bai","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2026061615215729700_jiag199-B9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2026061615215729700_jiag199-B10","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jama.2025.4288","article-title":"Management of Staphylococcus aureus bacteremia: a review","volume":"334","author":"Tong","year":"2025","journal-title":"JAMA"},{"key":"2026061615215729700_jiag199-B11","author":"Clinical and Laboratory Standards Institute"},{"key":"2026061615215729700_jiag199-B12","doi-asserted-by":"crossref","first-page":"104626","DOI":"10.1016\/j.idnow.2022.09.021","article-title":"Prevalence of a cefazolin inoculum effect associated with blaZ gene types, and clinical outcomes among methicillin-susceptible Staphylococcus aureus blood isolates of patients with infective endocarditis","volume":"53","author":"Bourreau","year":"2023","journal-title":"Infect Dis Now"},{"key":"2026061615215729700_jiag199-B13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus Network Adaptive Platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026061615215729700_jiag199-B14","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1093\/cid\/ciaa801","article-title":"Risk factors for recurrent Staphylococcus aureus bacteremia","volume":"72","author":"Choi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026061615215729700_jiag199-B15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2026061615215729700_jiag199-B16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/cid\/ciz535","article-title":"Resilience of the Pitt bacteremia score: 3 decades and counting","volume":"70","author":"Al-Hasan","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026061615215729700_jiag199-B17","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/cid\/ciz528","article-title":"The Pitt bacteremia score predicts mortality in nonbacteremic infections","volume":"70","author":"Henderson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026061615215729700_jiag199-B18","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2026061615215729700_jiag199-B19","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc"},{"key":"2026061615215729700_jiag199-B20","doi-asserted-by":"crossref","first-page":"111942","DOI":"10.1016\/j.jclinepi.2025.111942","article-title":"When and why to use overlap weighting: clarifying its role, assumptions, and estimand in real-world studies","volume":"187","author":"Rizk","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"2026061615215729700_jiag199-B21","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"2026061615215729700_jiag199-B22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2026061615215729700_jiag199-B23","doi-asserted-by":"crossref","first-page":"ofac096","DOI":"10.1093\/ofid\/ofac096","article-title":"What is the optimal follow-up length for mortality in Staphylococcus aureus bacteremia? Observations from a systematic review of attributable mortality","volume":"9","author":"Bai","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026061615215729700_jiag199-B24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.32614\/RJ-2022-011","article-title":"PSweight: an R package for propensity score weighting analysis","volume":"14","author":"Zhou","year":"2020","journal-title":"R J"},{"key":"2026061615215729700_jiag199-B25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10096-014-2241-5","article-title":"Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome","volume":"34","author":"Chong","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026061615215729700_jiag199-B26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Korea INfectious Diseases (KIND) study group. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026061615215729700_jiag199-B27","doi-asserted-by":"crossref","first-page":"e2451353","DOI":"10.1001\/jamanetworkopen.2024.51353","article-title":"\u03b2-lactam inoculum effect in methicillin-susceptible Staphylococcus aureus infective endocarditis","volume":"7","author":"Jean","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026061615215729700_jiag199-B28","doi-asserted-by":"crossref","first-page":"ofy123","DOI":"10.1093\/ofid\/ofy123","article-title":"The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"5","author":"Miller","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2026061615215729700_jiag199-B29","doi-asserted-by":"crossref","first-page":"e00703-20","DOI":"10.1128\/AAC.00703-20","article-title":"Cefazolin inoculum effect and methicillin-susceptible Staphylococcus aureus osteoarticular infections in children","volume":"64","author":"McNeil","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026061615215729700_jiag199-B30","doi-asserted-by":"crossref","first-page":"e02511-19","DOI":"10.1128\/AAC.02511-19","article-title":"Novel insights into the classification of staphylococcal \u03b2-lactamases in relation to the cefazolin inoculum effect","volume":"64","author":"Carvajal","year":"2020","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag199\/67782432\/jiag199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/e1433\/67782432\/jiag199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/e1433\/67782432\/jiag199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:22:07Z","timestamp":1781637727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/6\/e1433\/8586349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag199","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,4,2]]}}}